Directed Therapies in Lung Cancer: New Hope?

被引：3
|
作者：
Parente Lamelas, Isaura [1 ]
Abal Arca, Jose [1 ]
Firvida Perez, Jose Luis [2 ]
机构：
[1] Complexo Hosp Univ Ourense, Serv Neumol, Orense, Spain
[2] Complexo Hosp Univ Ourense, Med Oncol Serv, Orense, Spain
来源：
ARCHIVOS DE BRONCONEUMOLOGIA | 2012年 / 48卷 / 10期
关键词：
Lung cancer; Epidermal growth factor receptor; Vascular endothelial growth factor; Anaplastic lymphoma kinase; Erlotinib; Gefitinib; Bevacizumab; Crizotinib; GROWTH-FACTOR-RECEPTOR; EML4-ALK FUSION GENE; PHASE-III; OPEN-LABEL; 1ST-LINE THERAPY; GEFITINIB; MUTATIONS; SURVIVAL; ERLOTINIB; CHEMOTHERAPY;
D O I：
10.1016/j.arbres.2012.03.007
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Lung cancer (LC) is a serious health problem due to its high incidence and mortality. Surgery is the most effective therapeutic strategy in this type of tumor, but in recent years new drugs are being investigated that target specific components of the tumor cells, improving survival in patients with advanced disease and relapse. We present a review of individualized treatments in LC, particularly therapies that inhibit epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) and anaplastic lymphoma kinase (ALK). (c) 2011 SEPAR. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码：367 / 371
页数：5
相关论文
共 50 条
  • [41] Targeted therapy in nonsmall cell lung cancer
    Puri, T.
    INDIAN JOURNAL OF CANCER, 2017, 54 (01) : 83 - 88
  • [42] Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?
    Buffoni, Lucio
    Vavala, Tiziana
    Novello, Silvia
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (10)
  • [43] Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population
    Aguiar, Filipa
    Fernandes, Gabriela
    Queiroga, Henrique
    Machado, Jose Carlos
    Cirnes, Luis
    Moura, Conceicao Souto
    Hespanhol, Venceslau
    ARCHIVOS DE BRONCONEUMOLOGIA, 2018, 54 (01): : 10 - 17
  • [44] Comparison of Treatment Outcome in EGFR Positive and Negative Patients with Non Small Cell Lung Cancer: A Longitudinal Study
    Khanum, Farzana
    Khan, Nafees Ahmad
    Firdaus, Huma
    Bhargava, Rakesh
    Ahmad, Zuber
    Shameem, Mohammad
    Akhtar, Kafil
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2023, 17 (01) : OC43 - OC47
  • [45] Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group
    Umemura, Shigeki
    Tsubouchi, Kazuya
    Yoshioka, Hiroshige
    Hotta, Katsuyuki
    Takigawa, Nagio
    Fujiwara, Keiichi
    Horita, Naokatsu
    Segawa, Yoshihiko
    Hamada, Noboru
    Takata, Ichiro
    Yamane, Hiromichi
    Kamei, Haruhito
    Kiura, Katsuyuki
    Tanimoto, Mitsune
    LUNG CANCER, 2012, 77 (01) : 134 - 139
  • [46] Biological markers in lung cancer: A clinician's perspective
    Tufman, Amanda
    Huber, Rudolph Maria
    CANCER BIOMARKERS, 2010, 6 (3-4) : 123 - 135
  • [47] New targeted therapies for non-small cell lung cancer
    Lee, Eun Hye
    Kwak, Se Hyun
    Kim, Chi Young
    Gwon, Hye Ran
    Kim, Eun Young
    Chang, Yoon Soo
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2023, 66 (03): : 180 - 190
  • [48] Clinical Experience With 75-mg Dose of Erlotinib for Mutated Metastatic EGFR Non-small Cell Lung Cancer
    Aren, Osvaldo
    Samtani, Suraj
    Frelinghuysen, Micahel
    Burotto, Mauricio
    AMERICAN JOURNAL OF THERAPEUTICS, 2021, 28 (04) : E375 - E379
  • [49] The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
    Wang, Chi
    Li, Yun
    Ke, Li
    Cao, Lejie
    Fan, Pingsheng
    Wu, Zhiwei
    Wu, Quan
    JOURNAL OF CANCER, 2019, 10 (04): : 885 - 892
  • [50] Recent advances in targeted advanced lung cancer therapy in the elderly
    Losanno, Tania
    Gridelli, Cesare
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (09) : 787 - 797
12345